Hsieh, P.-L.;                     Chu, P.-M.;                     Cheng, H.-C.;                     Huang, Y.-T.;                     Chou, W.-C.;                     Tsai, K.-L.;                     Chan, S.-H.    
        Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation. Int. J. Mol. Sci. 2022, 23, 10146.
    https://doi.org/10.3390/ijms231710146
    AMA Style
    
                                Hsieh P-L,                                 Chu P-M,                                 Cheng H-C,                                 Huang Y-T,                                 Chou W-C,                                 Tsai K-L,                                 Chan S-H.        
                Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation. International Journal of Molecular Sciences. 2022; 23(17):10146.
        https://doi.org/10.3390/ijms231710146
    
    Chicago/Turabian Style
    
                                Hsieh, Pei-Ling,                                 Pei-Ming Chu,                                 Hui-Ching Cheng,                                 Yu-Ting Huang,                                 Wan-Ching Chou,                                 Kun-Ling Tsai,                                 and Shih-Hung Chan.        
                2022. "Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation" International Journal of Molecular Sciences 23, no. 17: 10146.
        https://doi.org/10.3390/ijms231710146
    
    APA Style
    
                                Hsieh, P.-L.,                                 Chu, P.-M.,                                 Cheng, H.-C.,                                 Huang, Y.-T.,                                 Chou, W.-C.,                                 Tsai, K.-L.,                                 & Chan, S.-H.        
        
        (2022). Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation. International Journal of Molecular Sciences, 23(17), 10146.
        https://doi.org/10.3390/ijms231710146